BioAge Labs(NASDAQ) BIOA

BioAge Labs, Inc. makes drugs to treat diseases of aging. These medicines help patients with obesity and heart-related conditions. The company uses data to find ways to improve human health.

Targeting the Biology of Aging

• BGE-102: Oral drug candidate designed to block inflammation for treating heart disease and diabetic macular edema.
• APJ Agonists: Injectable and oral treatments that aim to help patients lose weight while keeping muscle.
• Discovery Platform: Proprietary technology used to identify drug targets by analyzing molecular changes in aging humans.

Strategic Deals and Clinical Steps

• Partnered with Novartis on Dec. 16, 2024, to find drug targets related to aging and exercise.
• Raised $123.6 million in net proceeds through an underwritten public offering in January 2026.
• Sold 2,400,000 shares of common stock through an at-the-market facility as of June 30, 2026.
• Dosed the first participant in a Phase 2 trial for BGE-102 in June 2026.
• Initiated collaborations with Eli Lilly and Company to advance earlier stage platform-derived programs.

What Makes BioAge Different?

BioAge uses large-scale human datasets to find drug targets that are often missed by traditional animal studies. The company focuses on a specific protein called NLRP3, using a unique binding site that is protected by issued patents.

A Look at the Numbers

• Cash, cash equivalents, and marketable securities totaled $381.3 million as of June 30, 2026.
• Net loss was $48.4 million for the six-month period ended June 30, 2026.
• Collaboration revenue reached $5.2 million for the six-month period ended June 30, 2026.
• Research and development expenses were $44.8 million for the six-month period ended June 30, 2026.
• Accumulated deficit grew to $381.8 million as of June 30, 2026.

The Final Word

BioAge has evolved from a discovery startup to a clinical-stage biotech company with multiple active programs for metabolic diseases. Its growth is supported by large pharmaceutical partnerships and a data-driven approach to targeting the aging process.